Latest Conference Articles

November 15th 2023, 11:40pm

Bridging the Gaps in Breast Cancer

Alison K. Conlin, MD, discusses the importance of targeting central nervous system metastases in the treatment of patients with breast cancer, highlighting ongoing treatment investigations for this population.

November 15th 2023, 11:37pm

Bridging the Gaps in Breast Cancer

Terry P. Mamounas, MD, discusses surgical de-escalation strategies in the treatment of patients with HER2-positive breast cancer.

November 15th 2023, 11:33pm

Bridging the Gaps in Breast Cancer

Aditya Bardia, MD, MPH, discusses the continued investigation of oral selective estrogen receptor degraders in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

November 14th 2023, 8:05pm

PER® New York Lung Cancer Symposium

Hossein Borghaei, DO, MS, discusses the importance of determining the most suitable treatment for patients with non–small cell lung cancer through the use of biomarker testing.

November 14th 2023, 7:36pm

PER® New York Lung Cancer Symposium

Stephen V. Liu, MD, discusses the benefits of conducting biomarker testing for patients with advanced non–small cell lung cancer and highlights the importance of waiting for the results before selecting a targeted treatment.

November 13th 2023, 8:31pm

PER® New York Lung Cancer Symposium

Stephen V. Liu, MD, discusses strategies for treatment and disease management for patients with advanced non–small cell lung cancer who are awaiting biomarker test results.

November 13th 2023, 6:12pm

PER® New York Lung Cancer Symposium

Ongoing research evaluating combination therapies for the frontline treatment of patients with EGFR-mutated non–small cell lung cancer could help improve survival outcomes for this patient population.

November 13th 2023, 5:50pm

PER® New York Lung Cancer Symposium

Nicholas C. Rohs, MD, delves into the details of the case study a patient who had a lung cancer relapse detected following a referral to a dermatologist due to pityriasis rubra pilaris.

November 12th 2023, 1:56am

Rutgers Cancer Institute of New Jersey's Annual Oncology Clinical Practice and Research Summit

Richard Lazzaro, MD, FACS, discusses the advantages of standard low-dose computed tomography scans in lung cancer screening in high-risk individuals, as well as future opportunities to integrate biomarker-based assays into screening protocols to improve early detection.

November 12th 2023, 12:25am

Rutgers Cancer Institute of New Jersey's Annual Oncology Clinical Practice and Research Summit

Bruce Haffty, MD, MS, discusses the significance of technical and biological advancements in approaches to radiotherapy, and how they engendered the de-escalation of radiotherapy for select patients with breast cancer.

November 11th 2023, 10:45pm

PER® New York Lung Cancer Symposium

Nicholas C. Rohs, MD, discusses a case study that he presented during the Interesting Cases session at the 18th Annual New York Lung Cancers Symposium®.

November 11th 2023, 10:20pm

PER® New York Lung Cancer Symposium

Benjamin Philip Levy, MD, discusses antibody-drug conjugates under investigation in patients with non–small cell lung cancer.

November 11th 2023, 8:58pm

PER® New York Lung Cancer Symposium

While there are considerable barriers to incorporating comprehensive genotyping, the use of circulating tumor DNA offers an improvement in molecular testing—and doing so earlier can accelerate the time to treatment and improve survival for patients with lung cancer.

November 11th 2023, 8:57pm

PER® New York Lung Cancer Symposium

As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.

November 11th 2023, 8:26pm

International Kidney Cancer Symposium

Although not immediately practice changing, CAR T-cell therapy has the potential to become a standard of care for patients with advanced renal cell carcinoma following progression on checkpoint inhibitors and VEGF inhibitors.

November 11th 2023, 7:45pm

International Kidney Cancer Symposium

Additional research exploring the association between clonal hematopoiesis and cardiovascular health could help improve outcomes for patients with kidney cancer and identify those at higher risk for experiencing cardiac events.

November 11th 2023, 7:44pm

International Kidney Cancer Symposium

Further understanding of the cancer immunity cycle could drive the development of novel immune therapies for patients with renal cell carcinoma.

November 11th 2023, 7:27pm

International Kidney Cancer Symposium

Decisions regarding the intensification or de-escalation of treatment, particularly with immunotherapy and TKIs, for patients with renal cell carcinoma could be aided by circulating tumor DNA.

November 11th 2023, 7:04pm

PER® New York Lung Cancer Symposium

Although the emergence of immunotherapy have created additional treatment options for patients with various types of cancer, these agents are associated with significant toxicities and immune-related adverse effects.

November 11th 2023, 6:28pm

International Kidney Cancer Symposium

Brian H. Ramnaraign, MD, discusses findings from a single-institution review of the incidence of immunotherapy-related toxicities in older patients with kidney cancer.